US EditionXanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover
- Researchers presented updated data from the Beamion LUNG-1 trial on zongertinib at the 2025 AACR Annual Meeting.
- This trial evaluates zongertinib, a HER2-targeted therapy, for previously treated advanced non-small cell lung cancer patients with HER2 mutations.
- Beamion LUNG-1 assesses zongertinib monotherapy in patients having HER2 mutations inside or outside the tyrosine kinase domain.
- In cohort 1 , zongertinib achieved a 71% overall response rate and 12.4 months median progression-free survival.
- The data supported the FDA granting priority review and suggest zongertinib offers clinically meaningful benefit with manageable side effects.
14 Articles
14 Articles
Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover
Non-small cell lung cancer (NSCLC) is a prevalent and fatal malignancy with a significant global impact. Recent advancements have introduced targeted therapies like tyrosine kinase inhibitors (TKIs) such as osimertinib, which have improved patient outcomes, particularly in those with EGFR mutations. Despite these advancements, acquired resistance to TKIs remains a significant challenge. Hence, one of the current research priorities is understand…
Boehringer's new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertin…
New Zongertinib Data From Boehringer Shows Sustained, Clinically Meaningful Results In Advanced NSCLC Patients
Image Credit: © Sebastian Kaulitzki – stock.adobe.com Boehringer Ingelheim has shared new data from the Phase Ib Beamion LUNG-1 clinical trial (NCT04886804) of zongertinib, an investigational irreversible tyrosine kinase inhibitor, in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). Zongertinib demonstrated clinically meaningful and sustainable results, with a median duration of response (DoR) of …
Boehringer’s HER2-mutated lung cancer drug shows sustained benefit for 14 months
After treatment with Boehringer's zongertinib, there was a median DoR of 14.1 months and median PFS of 12.4 months in NSCLC patients.The post Boehringer’s HER2-mutated lung cancer drug shows sustained benefit for 14 months appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- 67% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage